// App-Quantinova.ai

68 : Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Researchers

Presenter

  • Daniel W. Lee III

Principal Investigators

  • Nirali N Shah

  • Maryalice Stetler-Stevenson

  • Marianna Sabatino

  • Cindy Delbrook

  • Kelly Richards

  • James N Kochenderfer

  • Steven A. Rosenberg

  • David Stroncek

  • Alan S. Wayne

  • Crystal L Mackall

Medical Centers

  • Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

  • Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Surgery Branch, NIH, NCI, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Peripheral blood mononuclear cell

  • Coxsackie Virus And Adenovirus Receptor

  • Granulocyte-macrophage-colony stimulating factor

  • Twist-related protein 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Tocilizumab

  • fludarabine tablet

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved